260 results on '"Stramer, S."'
Search Results
52. Incidence Estimation Based on Seroconversion Among Repeat Donors: A Comparison of Two Methods: S104-040C
53. Evaluation of the Yield of Triggering and Detriggering Criteria for West Nile Virus (WNV) NAT: S69-030G
54. Symptomatology of West Nile Virus (WNV) Infection Identified in Blood Donors Who Test Reactive for WNV RNA: S70-030G
55. Highly Sensitive and Equivalent Detection of Dengue Virus Serotypes 1, 2, 3, and 4 with an Enhanced Transcription-Mediated Amplification Assay: S67-030G
56. Dengue Viremia in Donations from Puerto Rico During the 2007 Dengue Outbreak: S66-030G
57. Transfusion-Transmitted Trypanosoma cruzi in the U.S.: A South American Connection?: S40-020D
58. Sensitivity of Selective Testing for Antibody to Trypanosoma cruzi (T. cruzi): S38-020D
59. Investigation of Reported Cases of Suspected Transfusion Transmission of HIV: S2-010A
60. HBV NAT Yield and Donor Characteristics in US Blood Donors; Impact of Vaccine Breakthrough Infection (VBI) and Correlation with Modeled Yield: P3-020A
61. Prevalence and Incidence of HIV and HCV Infections Among Allogeneic Donations Since the Introduction of Nucleic Acid Testing in the United States: S1-010A
62. CLINICAL PERFORMANCE OF THE ABBOTT PRISM CHAGAS ASSAY: P-098
63. Biobanks of blood from donors and recipients of blood products
64. Occult hepatitis B infection in blood donors
65. Feasibility of Reentry of Donors Deferred for Repeated Detection of Antibody to HBc Antigen (anti-HBc): S75–040B
66. Improved PRISM® HBV Surface Antigen Assay: Enhanced Sensitivity Leads to Incremental Detection of HbsAg-Positive Blood Donors: S74–040B
67. Prevalence of Dengue Virus Nucleic Acid in Blood Donors in Puerto Rico: S60–030K
68. Genetic Study of WNV (WNV) Human Isolates from 2006 Reveals a New Isolate Carrying a Deletion at the 3′ NCR: S59–030K
69. US Blood Donor Screening for Trypanosoma cruzi: Clinical Studies and Early Assessment of Prevalence: P2–030A
70. Antibodies to a novel antigen in acute hepatitis C virus infections
71. PROTECTIVE ROLE OF NATURAL ANTIBODIES IN WNV INFECTION: IN VITRO INFECTIVITY OF WNV ID NAT REACTIVE PLASMAS CONTAINING SPECIFIC ANTIBODIES (IGM AND/OR IGG): P-097
72. Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004
73. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors
74. Performance of ORTHO® HCV core antigen and trak-C™ assays for detection of viraemia in pre-seroconversion plasma and whole blood donors
75. Comparisons Of Genomic Sequences Of West Nile Virus Isolated From Infected Blood Donors: SP422
76. Multi-Site Study Of The Procleix® WNV Assay Using The Enhanced Semi-Automated System Compared With The TIGRIS® Automated System: SP420
77. Multi-Site Study Of The Procleix® Ultriotrade Assay Using The Enhanced Semi-Automated System Compared With The TIGRIS® Automated System: SP227
78. Screening Of Tissue Donors For Detection Of HIV-1, HCV And WNV RNAAnd HBV DNA: SP224
79. Verification Of Visual Lipemia Sample Suitability By Quantitative Triglyceride Testing: SP199
80. Genetic Variability In West Nile Virus (WNV) Isolates From Blood Donors Specimens From 2002, 2003 And 2004 USA Epidemics: S6-030B
81. West Nile Virus Nat-Positive Human Plasma Containing WNV-IgM And IgG Antibodies Can Infect Vero Cells And Human Primary Macrophages In Culture: S2-030B
82. West Nile Virus Adheres To Human Red Blood Cells (RBC) In Whole Blood: S3-030B
83. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid amplification testing
84. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV
85. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV
86. Viral diagnostics in the arena of blood donor screening
87. Performance of the Procleix HIV-1/HCV Assay in Organ and Tissue Donor Serum Specimens
88. Third Reported US Case of Breakthrough HIV Transmission from NAT Screened Blood
89. Evaluation of an Alternate HIV Confirmatory Testing Algorithm
90. A West Nile Virus (WNV) Phase I Preclinical Study Using Frozen Repository Samples
91. West Nile Virus (WNV) RNA Prevalence in Blood Donations During the 2002 US Epidemic
92. Detection and Quantification of WNV RNA with a TaqMan RT-PCR Assay
93. West Nile Virus (WNV) Tests Identify Units Implicated in Tranfusion Transmission
94. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations
95. Use of the Procleix HIV-1 and HCV discriminatory assays to detect HIV and HCV RNA in whole blood
96. US NAT yield: where are we after 2 years?
97. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population
98. In Memoriam: Kenji Tadokoro, MD, PhD: 1947 - 2018
99. Detection of West Nile virus in blood donations--Puerto Rico, 2007
100. Vox sanguinis / Biobanks of blood from donors and recipients of blood products
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.